$30.99 $1.03 per serving
Product analysis
SAMe 400 mg offers a simple supplement with limited support for joint comfort and some context-dependent mood benefits. Its value falls in the middle of the available price comparison.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality40
The SAMe form is identified, but its preparation quality cannot be judged confidently. The form name alone does not establish stability or absorption.
Ingredient Transparency100
The SAMe amount and form are both disclosed. That makes it straightforward to compare the declared preparation and serving.
Value For Money50
The cost for the declared SAMe amount offers middling value. Its single-ingredient format makes that comparison relatively straightforward.
Customer Satisfaction76
Customer ratings are strongly positive across several hundred responses. They offer a satisfaction signal without confirming the expected benefits.
Product Focus71
SAMe has limited, context-dependent support for joint comfort and mood-related uses. Its metabolic role does not establish routine toxin clearance or dependable everyday stress relief.
- Format
Tablet - Container
- 30 Tablet(s)
- Per serving
- $1.03
- Customer rating
- 4.6 · 544 ratings
Goals
Impact
High effect
SAMe · 400 mg
Impact
Highest effect
SAMe · 400 mg
Impact
Moderate effect
SAMe · 400 mg
Impact
High effect
SAMe · 400 mg
SAMe Not classified
No linked studies yet.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
SAMe (SAMe Disulfate Tosylate) | 400 mg |
SAMe (SAMe Disulfate Tosylate) · 400 mg OverallScore81
400 mg of SAMe per serving comes at a high cost for the amount. A stabilized salt is indicated, though its specific form is unclear. Moisture protection from blister packaging is unclear. The active amount is disclosed.
How this ingredient is rated
Active Ingredient Quality & Bioavailability77
A stabilized salt is indicated, but its specific form is unclear. Blister packaging is not documented, leaving moisture protection unclear.
Stabilized Salt Form
A stabilized salt is indicated, but its specific form is unclear.
Packaging Integrity
Blister packaging is not documented, leaving moisture protection unclear.
Dose, Safety & Label Transparency100
The serving lists 400 mg of SAMe. The active SAMe amount is stated separately from its salt.
Active Dosage Strength
The serving lists 400 mg of SAMe.
Net SAMe Yield Transparency
The active SAMe amount is stated separately from its salt.
Value50
The cost for the listed SAMe amount is relatively high.
Price Per 400mg Active Dose
The cost for the listed SAMe amount is relatively high.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
- Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
- Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
- A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
- Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
- Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
- Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
- S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
- Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
- S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
- Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
- A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
- Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
- S-adenosylmethionine blood levels in major depression: changes with drug treatment.
- Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.